Leerink Swann started coverage on shares of Avedro (NASDAQ:AVDR) in a report published on Monday, The Fly reports. The firm issued an outperform rating and a $20.00 target price on the stock.
Separately, JPMorgan Chase & Co. initiated coverage on shares of Avedro in a research report on Monday. They set an overweight rating and a $16.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average price target of $19.40.
AVDR stock opened at $12.74 on Monday. Avedro has a 12 month low of $10.75 and a 12 month high of $13.65.
In other news, Director Gilbert H. Kliman acquired 25,000 shares of the business’s stock in a transaction on Tuesday, February 19th. The stock was bought at an average price of $14.00 per share, for a total transaction of $350,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.
Featured Story: Bull Market
Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.